The Lewis Katz School of Medicine at Temple University, located on the Health Science Campus of Temple University in Philadelphia, PA, is one of 7 schools of medicine in Pennsylvania conferring the M.D. degree. It also confers the Ph.D. and M.S. degrees in biomedical sciences.

During the past decade, Temple University School of Medicine conducted 37 clinical trials. In the 10-year time frame, 37 clinical trials started and 26 clinical trials were completed, i.e. on average, 70.3% percent of trials that started reached the finish line to date. In the past 5 years, 18 clinical trials started and 19 clinical trials were completed. i.e. 105.6% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Temple University School of Medicine" #1 sponsor was "Temple University" with 11 trials, followed by "National Institute of Allergy and Infectious Diseases (NIAID)" with 10 trials sponsored, "Cytokinetics" with 4 trials sponsored, "Mitsubishi Tanabe Pharma America Inc." with 4 trials sponsored and "Boehringer Ingelheim" with 4 trials sponsored. Other sponsors include 35 different institutions and companies that sponsored additional 41 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Temple University School of Medicine" #1 collaborator was "Eli Lilly and Company" with 2 trials as a collaborator, "Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)" with 2 trials as a collaborator, "Massachusetts General Hospital" with 2 trials as a collaborator, "Temple University" with 2 trials as a collaborator and "AbCellera Biologics Inc." with 1 trials as a collaborator. Other collaborators include 13 different institutions and companies that were collaborators in the rest 23 trials.

According to Clinical.Site data, the most researched conditions in "Temple University School of Medicine" are "HIV Infections" (12 trials), "Amyotrophic Lateral Sclerosis" (8 trials), "ALS" (3 trials), "Pregnancy" (3 trials) and "Amyotrophic Lateral Sclerosis (ALS)" (2 trials). Many other conditions were trialed in "Temple University School of Medicine" in a lesser frequency.

Most popular intervention types in "Temple University School of Medicine" are "Drug" (49 trials), "Device" (7 trials), "Other" (7 trials), "Procedure" (4 trials) and "Biological" (3 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (16 trials), "MT-1186" (3 trials), "Participating Site's standard practice" (2 trials), "Reldesemtiv" (2 trials) and "SRM003" (2 trials). Other intervention names were less common.

The vast majority of trials in "Temple University School of Medicine" are 67 trials for "All" genders, 4 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are 17 active trials in "Temple University School of Medicine". 1 are not yet recruiting, 6 are recruiting, 9 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 43 completed trials in Temple University School of Medicine, undefined suspended trials, and 9 terminated clinical trials to date.

Out of the total trials that were conducted in Temple University School of Medicine, 4 "Phase 1" clinical trials were conducted, 12 "Phase 2" clinical trials and 32 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 4 trials, and there were also 10 trials that are defined as “Not Applicable".